A jury in Puerto Rico has handed Pfizer its latest loss in litigation over its hormone treatment Prempro. A jury for the U.S. District Court for the District of Puerto Rico found that Pfizer failed to adequately warn about the risk of breast cancer associated with Prempro (conjugated estrogens/medroxyprogesterone acetate), which led to the plaintiff, Helen Rivera-Adams, developing the disease after taking the drug. The decision is the latest in a series of rulings that have gone against Pfizer in liability suits related to Prempro, which the company gained through its acquisition of Wyeth in 2009.
Washington Drug Letter
via fdanews.com
No comments:
Post a Comment